CDC: Some immunocompromised people can get fourth vaccine dose
The Centers for Disease Control and Prevention (CDC) issued updated guidance Monday saying some immunocompromised people can get a fourth COVID-19 vaccine dose for additional protection.
The federal agency permits moderately and severely immunocompromised adults to get a fourth booster shot if they completed an initial series of an mRNA vaccine and received a third additional dose. The fourth shot can be administered six months after the most recent dose.
The adjusted recommendations come days after the CDC approved mix-and-match booster shots, where a person receives a different brand dose from their initial vaccination.
Under this guidance, moderately and severely immunocompromised people who got the Pfizer-BioNTech or Moderna vaccines for their first three shots can get a different booster shot if desired.
The CDC distinguished the definitions for additional dose and booster shot, saying an additional dose referred to a subsequent shot for people thought not to have an adequate immune response to the initial vaccine series.
Booster shots, on the other hand, refer to a subsequent dose given to those whose protection from the initial vaccine series is expected to have decreased over time.
The CDC officially advised immunocompromised people to get a third additional dose of an mRNA vaccine in August, so the earliest third dose recipients would not be eligible for a fourth shot until February. The additional third shot was recommended at least 28 days after the second dose.
Immunocompromised Johnson & Johnson recipients received different instructions to get a single COVID-19 booster shot at least two months after their initial dose, just like all adults who got the single-dose shot.
The federal agency granted the option for specific Moderna and Johnson & Johnson recipients to get booster shots last week following a unanimous advisory panel vote.
While all Johnson & Johnson-vaccinated adults are advised to get a booster, the CDC recommended the extra shot to certain vulnerable Moderna and Pfizer-BioNTech populations, including those aged 65 and older, those in long-term care facilities and those aged 50 to 64 with underlying medical conditions.
The CDC also granted the option of a booster dose following an mRNA vaccine to other adults with underlying medical conditions and adults at risk of contracting COVID-19 due to their occupational or institutional setting.
The Pfizer-BioNTech vaccine was authorized to be given to these populations last month, ahead of the Moderna and Johnson & Johnson booster approvals.
The Hill has removed its comment section, as there are many other forums for readers to participate in the conversation. We invite you to join the discussion on Facebook and Twitter.